Aquestive Therapeutics Inc (NASDAQ:AQST) shares, rose in value, with the stock price up by 5.80% to the previous day’s close as strong demand from buyers drove the stock to $4.38.
Actively observing the price movement in the last trading, the stock closed the session at $4.14. The value of beta (5-year monthly) was 2.84. Referring to stock’s 52-week performance, its high was $6.23, and the low was $1.01. On the whole, AQST has fluctuated by 4.78% over the past month.
With the market capitalization of Aquestive Therapeutics Inc currently standing at about $394.07 million, investors are eagerly awaiting this quarter’s results, scheduled for Apr 30, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.08, which is expected to increase to -$0.07 for fiscal year -$0.37 and then to about -$0.3 by fiscal year 2025. Data indicates that the EPS growth is expected to be -184.60% in 2025, while the next year’s EPS growth is forecast to be 18.90%.
Analysts have estimated the company’s revenue for the quarter at $12.46 million, with a low estimate of $12 million and a high estimate of $13 million. According to the average forecast, sales growth in current quarter could jump up 11.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $50.22 million, representing an increase of 14.60% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that AQST’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AQST currently trading nearly -8.35% and 22.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.17, while the 7-day volatility ratio is showing 7.23% which for the 30-day chart, stands at 11.90%. Furthermore, Aquestive Therapeutics Inc (AQST)’s beta value is 2.91, and its average true range (ATR) is 0.46.
A comparison of Aquestive Therapeutics Inc (AQST) with its peers suggests the former has fared considerably weaker in the market. AQST showed an intraday change of 5.80% in last session, and over the past year, it grew by 284.21%%.
Data on historical trading for Aquestive Therapeutics Inc (NASDAQ:AQST) indicates that the trading volumes over the past 10 days have averaged 3.15 million and over the past 3 months, they’ve averaged 2.14 million. According to company’s latest data on outstanding shares, there are 89.97 million shares outstanding.
Nearly 6.92% of Aquestive Therapeutics Inc’s shares belong to company insiders and institutional investors own 26.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.32 million shares as on Mar 15, 2024, resulting in a short ratio of 0.7. According to the data, the short interest in Aquestive Therapeutics Inc (AQST) stood at 3.16% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 1.99 million. The stock has risen by 116.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AQST stock heading into the next quarter.
